PMID: 22874010

Marson FA, Bertuzzo CS, Hortencio TD, Ribeiro JD, Bonadia LC, Ribeiro AF
The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis.
BMC Pulm Med. 2012 Aug 8;12:41., [PubMed]
Sentences
No. Mutations Sentence Comment
27 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 22874010:27:270
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 22874010:27:263
status: NEW
view ABCC7 p.Arg553* details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 22874010:27:280
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:27:248
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:27:255
status: NEW
view ABCC7 p.Arg1162* details
Determination of mutations in the CFTR gene Determination of mutations in the CFTR gene was performed in the Laboratory of Molecular Genetics for mutations by polymerase chain reaction (F508del) and restriction fragment length polymorphism method (G542X, R1162X, R553X, G551D and N1303K). Login to comment
28 ABCC7 p.Gly551Asp
X
ABCC7 p.Gly551Asp 22874010:28:270
status: NEW
view ABCC7 p.Gly551Asp details
ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 22874010:28:263
status: NEW
view ABCC7 p.Arg553* details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 22874010:28:280
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:28:248
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:28:255
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Ile618Thr
X
ABCC7 p.Ile618Thr 22874010:28:163
status: NEW
view ABCC7 p.Ile618Thr details
Determination of mutations in the CFTR gene Determination of mutations in the CFTR gene was performed in the Laboratory of Molecular Genetics for mutations by polymerase chain reaction (F508del) and restriction fragment length polymorphism method (G542X, R1162X, R553X, G551D and N1303K). Login to comment
29 ABCC7 p.Ile618Thr
X
ABCC7 p.Ile618Thr 22874010:29:163
status: NEW
view ABCC7 p.Ile618Thr details
Some mutations in patients with CF were obtained by sequencing or MLPA (Multiplex Ligation-dependent Probe Amplification) analysis: S4X, 2183A > G, 1717-G > A and I618T. Login to comment
32 ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 22874010:32:49
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Pro205Ser
X
ABCC7 p.Pro205Ser 22874010:32:41
status: NEW
view ABCC7 p.Pro205Ser details
Others identified mutations as class IV (P205S e R334W) were included in the statistical analysis in the not identified mutation subgroup, to minimize the associated factor with the mutation classes in the CFTR gene, being that the class IV is associated with a minor severity. Login to comment
33 ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 22874010:33:49
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Pro205Ser
X
ABCC7 p.Pro205Ser 22874010:33:41
status: NEW
view ABCC7 p.Pro205Ser details
Others identified mutations as class IV (P205S e R334W) were included in the statistical analysis in the not identified mutation subgroup, to minimize the associated factor with the mutation classes in the CFTR gene, being that the class IV is associated with a minor severity. Login to comment
69 ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 22874010:69:333
status: NEW
view ABCC7 p.Arg553* details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 22874010:69:310
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:69:148
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:69:267
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:69:393
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:69:413
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:69:432
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:69:163
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:69:288
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:69:399
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:69:458
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:69:465
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Ile618Thr
X
ABCC7 p.Ile618Thr 22874010:69:419
status: NEW
view ABCC7 p.Ile618Thr details
The patients` CFTR genotypes were: 44 patients (24.44%) without identified mutation, 51 (28.33%) with one identified mutation (25% F508del/-, 2.78% G542X/-, 0.56% R1162X/-) and 85 (47.22%) patients with two identified mutations (31.67% F508del/F508del, 6.67% F508del/G542X, 2.78% F508del/R1162X, 2.22% F508del/N1303K, 0.56% F508del/ R553X, 0.56% F508del/S4X, 0.56% F508del/1717-1 G > A, 0.56% G542X/R1162X, 0.56% G542X/I618T, 0.56% G542X/2183A > G and 0.56% R1162X/R1162X). Login to comment
70 ABCC7 p.Arg553*
X
ABCC7 p.Arg553* 22874010:70:333
status: NEW
view ABCC7 p.Arg553* details
ABCC7 p.Asn1303Lys
X
ABCC7 p.Asn1303Lys 22874010:70:310
status: NEW
view ABCC7 p.Asn1303Lys details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:70:148
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:70:267
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:70:393
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:70:413
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Gly542*
X
ABCC7 p.Gly542* 22874010:70:432
status: NEW
view ABCC7 p.Gly542* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:70:163
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:70:288
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:70:399
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:70:458
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Arg1162*
X
ABCC7 p.Arg1162* 22874010:70:465
status: NEW
view ABCC7 p.Arg1162* details
ABCC7 p.Ile618Thr
X
ABCC7 p.Ile618Thr 22874010:70:419
status: NEW
view ABCC7 p.Ile618Thr details
The patients` CFTR genotypes were: 44 patients (24.44%) without identified mutation, 51 (28.33%) with one identified mutation (25% F508del/-, 2.78% G542X/-, 0.56% R1162X/-) and 85 (47.22%) patients with two identified mutations (31.67% F508del/F508del, 6.67% F508del/G542X, 2.78% F508del/R1162X, 2.22% F508del/N1303K, 0.56% F508del/ R553X, 0.56% F508del/S4X, 0.56% F508del/1717-1 G > A, 0.56% G542X/R1162X, 0.56% G542X/I618T, 0.56% G542X/2183A > G and 0.56% R1162X/R1162X). Login to comment
98 ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 22874010:98:49
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Pro205Ser
X
ABCC7 p.Pro205Ser 22874010:98:41
status: NEW
view ABCC7 p.Pro205Ser details
Others identified mutations as class IV (P205S e R334W) was included in the statistical analysis in the not identified mutation subgroup, to minimize the associated factor with the mutation classes in the CFTR gene. Login to comment
99 ABCC7 p.Arg334Trp
X
ABCC7 p.Arg334Trp 22874010:99:49
status: NEW
view ABCC7 p.Arg334Trp details
ABCC7 p.Pro205Ser
X
ABCC7 p.Pro205Ser 22874010:99:41
status: NEW
view ABCC7 p.Pro205Ser details
Others identified mutations as class IV (P205S e R334W) was included in the statistical analysis in the not identified mutation subgroup, to minimize the associated factor with the mutation classes in the CFTR gene. Login to comment